Lexaria Bioscience (NASDAQ:LEXX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lexaria Bioscience (NASDAQ:LEXX) to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings downgraded Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $22.50.

Lexaria Bioscience Stock Performance

NASDAQ LEXX opened at $3.27 on Friday. The firm has a 50-day simple moving average of $6.73 and a 200 day simple moving average of $8.98. Lexaria Bioscience has a twelve month low of $2.77 and a twelve month high of $21.60. The stock has a market cap of $6.90 million, a PE ratio of -0.64 and a beta of 0.61.

Lexaria Bioscience (NASDAQ:LEXX) last released its earnings results on Monday, July 13th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Research analysts forecast that Lexaria Bioscience will post -4.05 earnings per share for the current fiscal year.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds.

The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients.